SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED Funds and ETFs SciClone Pharmaceuticals (Holdings) Limited
Equities
6600
KYG4271B1023
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18 HKD | +0.11% |
|
0.00% | +29.31% |
| 04-18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
| 04-01 | SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit | MT |
ETFs positioned on SciClone Pharmaceuticals (Holdings) Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 4 M€ | -27.92% | ||
| 0.05% | 12 M€ | -16.71% | - |
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
16.66
CNY
Average target price
16.5
CNY
Spread / Average Target
-0.99%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.31% | 1.4B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 6600 Stock
- Funds and ETFs SciClone Pharmaceuticals (Holdings) Limited
